心臟生物標記市場規模、佔有率和成長分析（按產品、應用、檢測施行地點和地區分類）－2026-2033年產業預測

預計到 2024 年，心臟生物標記市場規模將達到 119.5 億美元，到 2025 年將達到 134.7 億美元，到 2033 年將達到 349.8 億美元，在預測期（2026-2033 年）內，複合年成長率為 12.67%。

心臟生物標記是心臟壓力或損傷時釋放的重要血液成分，在心臟衰竭和心肌梗塞等心臟相關疾病的診斷和治療中發揮著至關重要的作用。心血管疾病盛行率的上升、人們對早期診斷益處的認知不斷提高、對個人化醫療的需求日益成長以及生物標記技術的進步，都推動了這些生物標記市場的發展。然而，挑戰仍然存在，例如先進的生物標記檢測高成本且缺乏標準化，這可能導致結果不一致。儘管存在這些障礙，但在持續的技術創新、對預防醫學的高度重視以及醫療保健成本不斷上漲的推動下，該市場仍呈現出成長動能。這為更有效的心臟護理解決方案創造了機會。

心臟生物標記市場促進因素

人們對早期發現心臟病益處的認知不斷提高，大大推動了心臟生物標記市場的成長。隨著越來越多的人意識到早期識別心血管疾病的重要性，人們更加重視利用先進的診斷方法來預防疾病進展並降低醫療成本。此外，蛋白質體學和基因組學的進步使得制定針對個別生物標記物譜的個人化有效治療方案成為可能，這進一步激發了人們對心臟生物標記解決方案的興趣和投資。這種向預防性醫療策略的轉變凸顯了心臟生物標記在現代醫學中的關鍵作用。

心臟生物標記市場面臨的限制

由於新生物標記的檢驗過程漫長，需要大規模的縱向研究和臨床試驗，心臟生物標記市場面臨許多挑戰。這種漫長的檢驗過程可能會阻礙新生物標記的應用，進而抑制市場成長。此外，患者人口統計學特徵和合併症等因素導致生物標記水平存在差異，進而造成結果不一致，進一步加劇了這個問題，影響了檢測結果的可靠性。這些限制凸顯了建立可靠生物標記的難度，也是限制心臟生物標記市場整體發展和擴張的主要阻礙因素。

心臟生物標記市場趨勢

在心臟生物標記市場中，多生物標記檢測組合的應用顯著成長，這主要得益於人們越來越傾向於採用比傳統單標記物檢測更全面的評估方式。這些組合能夠幫助醫療專業人員更全面地評估與壓力、心臟損傷和發炎等因素相關的心血管風險。鑑於心臟疾病日益複雜，人們正在研究多生物標記檢測方法在增強風險分層和改善患者預後方面的潛力，尤其是在單一生物標記可能無法提供足夠資訊的困難病例中。這一趨勢標誌著心臟護理領域正朝著個人化醫療的方向邁進。

目錄

介紹

• 調查目標
• 定義
• 市場覆蓋範圍

調查方法

• 資訊收集
• 二手和一手資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

前景
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 抑制因素
  • 任務
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 技術分析
• 專利分析
• 價值鏈分析
• 監管分析

心臟生物標記市場（按產品分類）

• 肌鈣蛋白
• CK-MB
• 肌紅蛋白
• BNP 和 NT-proBNP
• 其他

按應用分類的心臟生物標記市場

• 急性冠狀動脈症候群
• 心肌梗塞
• 鬱血性心臟衰竭
• 其他

按檢測地點分類的心臟生物標記市場

• 檢查室檢測
• 就地檢驗

按地區分類的心臟生物標記市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲（MEA）
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市佔率（2025 年）

主要企業簡介

• Abbott
• QuidelOrtho Corporation
• Siemens AG
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Biomerieux SA
• Bio-Rad Laboratories, Inc.
• Randox Laboratories Ltd.
• Creative Diagnostics
• Life Diagnostics
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• DiaSorin
• Myriad RBM
• Mindray Medical International Limited
• ReLIA Diagnostic Systems
• Merck KGaA
• Quanterix Corporation
• Eurofins Scientific
• Inova Diagnostics

結論與建議

Cardiac Biomarkers Market size was valued at USD 11.95 Billion in 2024 and is poised to grow from USD 13.47 Billion in 2025 to USD 34.98 Billion by 2033, growing at a CAGR of 12.67% during the forecast period (2026-2033).

Cardiac biomarkers are crucial blood components released during heart stress or damage, playing a vital role in diagnosing and managing heart-related conditions such as heart failure and myocardial infarction. The market for these biomarkers is propelled by the rising prevalence of cardiovascular diseases, heightened awareness around early diagnostic benefits, an increasing demand for personalized medicine, and advancements in biomarker technology. However, challenges remain, including the high costs associated with advanced biomarker testing and a lack of standardization, which can lead to inconsistencies in results. Despite these obstacles, the market is poised for growth, fueled by ongoing innovations, a strong focus on preventive healthcare, and escalating healthcare expenditures. This creates opportunities for more effective cardiac care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cardiac Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cardiac Biomarkers Market Segments Analysis

Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cardiac Biomarkers Market

The rising awareness about the advantages of early detection of heart diseases has significantly contributed to the growth of the cardiac biomarkers market. As more individuals recognize the importance of identifying cardiovascular issues early, there is a heightened focus on utilizing advanced diagnostic methods to prevent disease progression and reduce healthcare expenses. Additionally, advancements in proteomics and genomics are facilitating the development of personalized and effective treatment plans tailored to individual biomarker profiles, further driving interest and investment in cardiac biomarker solutions. This shift towards proactive healthcare strategies underscores the critical role of cardiac biomarkers in modern medical practice.

Restraints in the Cardiac Biomarkers Market

The cardiac biomarkers market faces significant challenges due to the lengthy process required for validating novel biomarkers, which mandates extensive longitudinal studies and clinical trials. This lengthy validation process can hinder the introduction of new biomarkers, ultimately stunting market growth. Additionally, inconsistent results arising from variations in biomarker levels-attributed to factors such as patient demographics and comorbidities-further complicate the situation, affecting the reliability of test outcomes. These limitations underscore the difficulties in establishing dependable biomarkers, which poses a substantial restraint on the overall advancement and expansion of the cardiac biomarkers market.

Market Trends of the Cardiac Biomarkers Market

The cardiac biomarkers market is witnessing a notable shift towards the adoption of multi-biomarker panels, reflecting a growing preference for comprehensive evaluation over traditional single-marker testing. These panels enable healthcare professionals to conduct a more thorough assessment of cardiovascular risks associated with factors such as stress, cardiac injury, and inflammation. As the complexity of cardiac conditions increases, multi-biomarker approaches are being investigated for their potential to enhance risk stratification and improve patient outcomes, particularly in challenging cases where individual biomarkers may lack sufficient insight. This trend signifies a transformative movement towards personalized medicine in cardiac care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Patent Analysis
• Value Chain Analysis
• Regulatory Analysis

Cardiac Biomarkers Market By Product

• Market Overview
• Troponin
• CK-MB
• Myoglobin
• BNP & NT-proBNP
• Others

Cardiac Biomarkers Market By Application

• Market Overview
• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others

Cardiac Biomarkers Market By Location of Testing

• Market Overview
• Laboratory Testing
• Point of Care Testing

Cardiac Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Life Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad RBM
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReLIA Diagnostic Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inova Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation